The poor clinical outcome of rare EGFR mutation-dominant subtypes was further validated using an external cohort of 22 compound EGFR mutation-positive NSCLC patients obtained from the Memorial Sloan Kettering Cancer Center (MSKCC) database (Additional file 1: Fig. S3A). Here, EGFR is linked to non-small cell lung carcinoma.